Studies find that hypoglycemic drugs like Metformin, Dipeptidyl peptidase IV inhibitors (DPP4is) and glucagon-like peptide-1 (GLP-1) receptor agonists (Ras), sodium-glucose cotransporter 2 inhibitors (SGLT2is) are effective in treating Alzheimer’s disease by regulating insulin pathways and energy metabolism. This evidence concerns the gene INS and Alzheimer disease.